Date: 2017-02-21
Type of information: Production agreement
Compound: GX-H9 - recombinant growth hormone fused to hyFc
Company: Genexine (Republic of Korea) CMC Biologics (Denmark - USA)
Therapeutic area:
Type agreement: manufacturing - bioproduction
Action mechanism:
- hormone. GX-H9 is next-generation, long-acting recombinant human growth hormone (rhGH) consisting of recombinant growth hormone genetically fused to Genexine’s proprietary hybrid Fc (hyFc) platform, giving it extended half-life and potentially better safety profile. Compared to the current daily injection therapy, GX-H9 is being evaluated as weekly and twice-monthly dosing regimens to treat growth hormone deficiency (GHD).
- GX-H9 is being co-developed with Handok under a strategic partnership. It has been granted orphan drug designation for the treatment of growth hormone deficiency in the US.
Disease:
Details: • On February 21, 2017, CMC Biologics and Genexine announced that they have entered into a manufacturing agreement for the process transfer and cGMP manufacturing of Genexine’s GX-H9.
Financial terms:
Latest news:
Is general: Yes
